NuPathe dumps Endo

Share this article:

Teva has swept in and upset Endo's NuPathe merger. Endo issued a statement Monday that NuPathe rejected Endo's bid, which meant coughing up a $5-million termination fee in order to go forward with Teva.

Specialty pharmaceutical company Endo offered $104 million for the company, but Business Week says Teva topped this by offering $144 million.

The deal means NuPathe's Zecuity migraine patch will now belong to Teva.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.